BEREA, Ohio (AP) — Myles Garrett didn't know he had joined a prestigious list of defensive stars last week until one of his biggest fans pointed it out to him. “My dad was hyped about it,” he said. For good reason. With three sacks last week in Cleveland's 24-19 win in prime time over the Pittsburgh Steelers, Garrett became the seventh player to reach double-digit sacks in seven straight seasons since the stat became official in 1982. The others: Lawrence Taylor (1984-90), Reggie White (1985-93), Bruce Smith (1992-98), John Randle (1992-99), DeMarcus Ware (2006-12) and Jared Allen (2007-13). All of them is in the Hall of Fame except for Allen. “Hall of Famer,” Garrett said in praising the retired Minnesota Vikings edge rusher, who is again on the doorstep of induction as a semifinalist for the fifth straight year. Garrett is on track to get his own bronze bust one day in Canton, but until then, he's humbled to be in such elite company. “Guys I looked up to when I started my journey into this game,” said Garrett, who tries to bolster his resume on Monday night when the Browns (3-8) visit the Denver Broncos (7-5). “It’s absolutely amazing to be amongst those guys, not just looking up at them but looking side to side and standing amongst them. "So I want to continue to find myself on those lists and hopefully stand alone at the end of the day.” He's on his way. The NFL's reigning Defensive Player of the Year is having another monster season but probably not getting the recognition he deserves as the Browns, upended by continuous quarterback issues, have fallen way short of expectations. Garrett used the national TV platform against the Steelers to remind any detractors of his greatness. He sacked Russell Wilson three times, forced a fumble and outplayed Pittsburgh's T.J. Watt, the player to whom he is most often compared. The Garrett vs. Watt debate went to another level in February. On the day Garrett received his DPOY award, second-place finisher Watt seemed to take a shot at the Browns star by posting “Nothing I'm not used to” on social media. Those comments stuck with Garrett, who following the win over Pittsburgh — and Watt being held without a sack — didn't hold back in declaring himself the league's best pass rusher. “I wanted to make it known that I’m the guy, I’m the No. 1 edge defender,” Garrett said. It was an unusual boast from Garrett, who was asked why he felt he needed to express himself. “Because part of my journey of being the best player that I can be is I think I can be the best player that there is currently,” he said. ”So I have to live up to those expectations I have for myself. That’s just on the road to be the player that I want to be.” Garrett's unrelenting drive is what sets him apart. Although he'll enter Monday's game with 98 1/2 sacks and can become just the fifth player to reach 100 in his first eight seasons, joining White, Ware, Allen and Watt, it's not enough. “I still took too long,” said Garrett, who can become the first to do it before turning 29. “It’d have been tough to catch Mr. White, but hopefully this next however many number will come quicker than the first 100. So we’ll go out there and we’ll do what I do and try to take it up a notch.” Browns defensive coordinator Jim Schwartz marvels at Garrett's output despite double- and triple-team blocking. “He just continues to do stuff,” Schwartz said. “His production is so high, even though he’s a marked man, even though every game plan starts with, ‘Don’t let 95 wreck the game,’ and he still finds a way to wreck games.” Schwartz doesn't need to see any lists to know Garrett belongs among the best to ever rush a quarterback. “Yes, he does,” Schwartz said. "I think he’s just starting to hit his prime. I think he still has a lot left in front of him. The sky is the limit as far as he goes. And when it’s all said and done, maybe you’re comparing other people to him. That should probably be a goal for him.” AP NFL: https://apnews.com/hub/nfl
Elon Musk’s preschool is the next step in his anti-woke education dreams
Glassboro over Ocean City in Boardwalk Classic - Girls basketball recap
NoneBEREA, Ohio (AP) — Myles Garrett didn't know he had joined a prestigious list of defensive stars last week until one of his biggest fans pointed it out to him. “My dad was hyped about it,” he said. For good reason. With three sacks last week in Cleveland's 24-19 win in prime time over the Pittsburgh Steelers, Garrett became the seventh player to reach double-digit sacks in seven straight seasons since the stat became official in 1982. The others: Lawrence Taylor (1984-90), Reggie White (1985-93), Bruce Smith (1992-98), John Randle (1992-99), DeMarcus Ware (2006-12) and Jared Allen (2007-13). All of them is in the Hall of Fame except for Allen. “Hall of Famer,” Garrett said in praising the retired Minnesota Vikings edge rusher, who is again on the doorstep of induction as a semifinalist for the fifth straight year. Garrett is on track to get his own bronze bust one day in Canton, but until then, he's humbled to be in such elite company. “Guys I looked up to when I started my journey into this game,” said Garrett, who tries to bolster his resume on Monday night when the Browns (3-8) visit the Denver Broncos (7-5). “It’s absolutely amazing to be amongst those guys, not just looking up at them but looking side to side and standing amongst them. "So I want to continue to find myself on those lists and hopefully stand alone at the end of the day.” He's on his way. The NFL's reigning Defensive Player of the Year is having another monster season but probably not getting the recognition he deserves as the Browns, upended by continuous quarterback issues, have fallen way short of expectations. Garrett used the national TV platform against the Steelers to remind any detractors of his greatness. He sacked Russell Wilson three times, forced a fumble and outplayed Pittsburgh's T.J. Watt, the player to whom he is most often compared. The Garrett vs. Watt debate went to another level in February. On the day Garrett received his DPOY award, second-place finisher Watt seemed to take a shot at the Browns star by posting “Nothing I'm not used to” on social media. Those comments stuck with Garrett, who following the win over Pittsburgh — and Watt being held without a sack — didn't hold back in declaring himself the league's best pass rusher. “I wanted to make it known that I’m the guy, I’m the No. 1 edge defender,” Garrett said. It was an unusual boast from Garrett, who was asked why he felt he needed to express himself. “Because part of my journey of being the best player that I can be is I think I can be the best player that there is currently,” he said. ”So I have to live up to those expectations I have for myself. That’s just on the road to be the player that I want to be.” Garrett's unrelenting drive is what sets him apart. Although he'll enter Monday's game with 98 1/2 sacks and can become just the fifth player to reach 100 in his first eight seasons, joining White, Ware, Allen and Watt, it's not enough. “I still took too long,” said Garrett, who can become the first to do it before turning 29. “It’d have been tough to catch Mr. White, but hopefully this next however many number will come quicker than the first 100. So we’ll go out there and we’ll do what I do and try to take it up a notch.” Browns defensive coordinator Jim Schwartz marvels at Garrett's output despite double- and triple-team blocking. “He just continues to do stuff,” Schwartz said. “His production is so high, even though he’s a marked man, even though every game plan starts with, ‘Don’t let 95 wreck the game,’ and he still finds a way to wreck games.” Schwartz doesn't need to see any lists to know Garrett belongs among the best to ever rush a quarterback. “Yes, he does,” Schwartz said. "I think he’s just starting to hit his prime. I think he still has a lot left in front of him. The sky is the limit as far as he goes. And when it’s all said and done, maybe you’re comparing other people to him. That should probably be a goal for him.” AP NFL: https://apnews.com/hub/nfl
Elon Musk, Vivek Ramaswamy start ‘brainstorming’ with Congress to cut government spending
The Federal Government, through the Ministry of Agriculture and Food Security and Fundação Getulio Vargas of Brazil, have signed a Memorandum of Understanding to advance private sector development in fertiliser production, hybrid seed technology, and agricultural finance. The MoU was signed on behalf of the government by the Permanent Secretary of FMAFS, Mr Temitope Fashedemi, and the President of FGV, Prof Carlos Ivan Simonsen Leal, at FGV Headquarters in Rio de Janeiro, Brazil, on the sidelines of the G20 Leaders’ Summit. “Under the MOU, private-sector projects on fertiliser production, hybrid seed technology, and agricultural financing are projected to attract $4.3bn in private-sector investment,” the State House Director of Information and Publicity, Mr. Abiodun Oladunjoye, revealed in a statement Sunday. The statement is titled, ‘Nigeria, Brazil sign MOU to boost agribusiness in 774 Local Government Areas.’ Oladunjoye said the agreement marks a new phase of strategic collaboration between Nigeria and FGV, the Green Imperative Project lead implementer, one of the largest international agricultural technology transfer initiatives. “Conceived in 2018, GIP is a $1.2bn cooperative effort between Brazil and Nigeria, designed to modernise Nigeria’s agricultural sector through Brazilian expertise in tropical agriculture. Related News Seadogs warn of debt crisis as Nigeria seeks $2.2bn loan Nigeria, two others lead countries with health, care visa Tinubu, wife return to Abuja after G20 Summit in Brazil “Since the MoU was conceived in 2018, both parties have engaged in many meaningful discussions to advance its design and implementation. “The project, supported by Deutsche Bank, aims to deliver transformative agricultural technologies and knowledge transfer over its 10-year duration,” he stated. Accordingly, over the next five years, the project will identify and support one agribusiness in Nigeria’s 774 local government areas with technical and financial resources, driving sustainable development and economic growth. “This partnership paves the way for Brazil to engage with Nigeria’s dynamic and rapidly growing agricultural sector. “Together with FGV, we are poised to unlock the potential of private sector investment in key areas critical to our food security,” Fashedemi said at the signing ceremony. Senior members of Nigeria’s presidency, officials of FMAFS, and FGV’s leadership attended the signing ceremony.OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan ; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada ; CEO: Clarissa Desjardins; "Congruence") to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, RevenirTM. Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, RevenirTM. Ono will obtain an exclusive option right to develop, manufacture and commercialize the identified small molecule correctors worldwide. Congruence will be eligible to receive an upfront payment, research expenses, milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales. "We believe that this collaboration with Congruence may help generating novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology, leading to our development pipeline," said Seishi Katsumata , Corporate Officer / Executive Director, Discovery & Research of Ono. "We will be committed to delivering innovative new drugs to cancer patients as soon as possible." "Congruence is thrilled to partner with Ono, which has established itself as a global leader in drug development, particularly in the oncology space. We believe that our RevenirTM platform and capabilities in protein dynamics will accelerate the discovery of novel therapies for compelling targets of interest to both companies," said Sharath Hegde PhD, Chief Scientific Officer of Congruence. About RevenirTM Drug Discovery Platform RevenirTM, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, RevenirTM predicts small molecule induced correction of the underlying defect. About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Congruence's proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. For more information, please visit www.congruencetx.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/ono-enters-into-drug-discovery-collaboration-agreement-with-congruence-therapeutics-to-generate-novel-small-molecule-correctors-in-the-oncology-area-302324452.html SOURCE Ono Pharmaceutical co., ltd.
Netherlands claimed a hard-fought 1-0 lead over Germany in the Davis Cup semifinals on Friday as Botic van de Zandschulp beat Daniel Altmaier 6-4, 6-7 (12/14), 6-3 in the first singles rubber. The Dutch have never reached the competition's final since first participating 104 years ago but knocked out Rafael Nadal's Spain in the last eight on Tuesday. Jan-Lennard Struff sought three-time winners Germany's hopes alive in the second singles match against Tallon Griekspoor. Van de Zandschulp claimed his scrappy victory with his 10th match point in two hours 44 minutes. "It could have been easier but I did it the hard way," said the Dutchman. "At some point, I didn't know what to do any more on the match points." Neither player blinked in a first set with few thrills, until the Dutchman, ranked 80th, nosed ahead for a 5-4 lead which he served out, clinching when Altmaier went wide. Van de Zandschulp, the final player to beat retiring superstar Nadal when the Netherlands knocked out Spain, broke in the fifth game of the second set and consolidated for a 4-2 lead, taking full control of the match. The Dutchman forced four break points in the next game, but the world number 88 managed to escape with three aces to avoid a double break. Moving into a higher gear the German was able to get back on serve at 4-4, converting his third break point at the end of the match's longest rally when Van de Zandschulp failed at the net. The Dutch player brought up five match points in the tie-break but could not hold his nerve and Altmaier took his fourth set point with a smash to force a third set. Van de Zandschulp broke in the second game, but Altmaier immediately responded. The Dutchman produced another break of serve to open up a 5-3 lead and, after wasting four more match points, wrapped up the win with his 10th as Altmaier could not return a powerful serve. "I had the toughest match of my life on Tuesday (against Nadal), so everything that comes next is a little bit easier," added Van de Zandschulp.Giants will try to snap a 7-game losing streak when they host the SaintsOSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan ; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada ; CEO: Clarissa Desjardins; "Congruence") to generate novel small molecule correctors against multiple protein targets in the oncology area by leveraging Congruence's proprietary drug discovery platform, RevenirTM. Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, RevenirTM. Ono will obtain an exclusive option right to develop, manufacture and commercialize the identified small molecule correctors worldwide. Congruence will be eligible to receive an upfront payment, research expenses, milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales. "We believe that this collaboration with Congruence may help generating novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology, leading to our development pipeline," said Seishi Katsumata , Corporate Officer / Executive Director, Discovery & Research of Ono. "We will be committed to delivering innovative new drugs to cancer patients as soon as possible." "Congruence is thrilled to partner with Ono, which has established itself as a global leader in drug development, particularly in the oncology space. We believe that our RevenirTM platform and capabilities in protein dynamics will accelerate the discovery of novel therapies for compelling targets of interest to both companies," said Sharath Hegde PhD, Chief Scientific Officer of Congruence. About RevenirTM Drug Discovery Platform RevenirTM, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, RevenirTM predicts small molecule induced correction of the underlying defect. About Congruence Therapeutics Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Congruence's proprietary scalable platform, RevenirTM, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. For more information, please visit www.congruencetx.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/ono-enters-into-drug-discovery-collaboration-agreement-with-congruence-therapeutics-to-generate-novel-small-molecule-correctors-in-the-oncology-area-302324452.html SOURCE Ono Pharmaceutical co., ltd.
Central Connecticut State defeats Binghamton 64-56